Genea Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Genea Limited - overview
Established
1986
Location
Sydney, NSW, Australia
Primary Industry
Healthcare
About
Genea Limited, based in Sydney, Australia, specializes in providing comprehensive fertility services designed to assist individuals and couples in their conception journey through advanced reproductive technologies. Genea Limited, founded in 1986 in Sydney, Australia, focuses on fertility services. The company has undergone strategic pivots to enhance its offerings but remains committed to its core competency in assisted reproductive technologies. Genea was acquired by Liverpool Partners in May 2022, though financial terms were not disclosed.
The company operates clinics across major Australian cities including New South Wales, Adelaide, Brisbane, Melbourne, Canberra, and Perth. The current CEO is Tim Yeoh, alongside Tomas Stojanov. Genea Fertility specializes in comprehensive fertility services aimed at assisting individuals and couples in their journey to conceive. Their core offerings include a range of fertility treatments, diagnostic tests, and genetic testing services tailored to meet the unique needs of each patient.
These services utilize advanced, proprietary fertility technologies exclusive to Genea in Australia, contributing to consistently higher-than-average success rates in assisted reproductive technologies. The company serves a diverse clientele, including single parents, couples facing infertility challenges, and LGBTIQA+ families, promoting an inclusive environment for all. In 2021, Genea Fertility reported a revenue of AUD 42,976,761. 40 and an EBITDA of AUD 2,666,093.
20. The company generates revenue primarily through direct transactions with individuals and couples seeking fertility assistance, reflecting their commitment to high-quality care. Following the acquisition by Liverpool Partners in May 2022, Genea Limited is focused on expanding its services and product offerings. Plans include the introduction of new fertility treatments and enhancements to existing services to better meet client needs.
The company aims to expand its geographic reach beyond Australia, although specific target regions have not been disclosed. The recent acquisition will facilitate the necessary funding to support these initiatives and strategic growth.
Current Investors
Primary Industry
Healthcare
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Clinics/Outpatient Services
Website
www.genea.com.au
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Genea Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Genea Adelaide | - | ||||||||
| Buyout | Completed | Genea Limited | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.